lamivudine HIV
Selected indexed studies
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (Drugs, 2020) [PMID:31865558]
- Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection. (Med Lett Drugs Ther, 2019) [PMID:31581158]
- Lamivudine for the treatment of HIV. (Expert Opin Drug Metab Toxicol, 2010) [PMID:20001611]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (2020) pubmed
- Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection. (2019) pubmed
- Dolutegravir plus lamivudine for the treatment of HIV-1 infection. (2020) pubmed
- Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. (2025) pubmed
- Lamivudine for the treatment of HIV. (2010) pubmed
- Dolutegravir, abacavir and lamivudine as HIV therapy. (2014) pubmed
- Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review. (2025) pubmed
- A comparative study based on ainuovirine/lamivudine/tenofovir against HIV-1. (2024) pubmed
- Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. (2015) pubmed
- Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. (2018) pubmed